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A B S T R A C T
Purpose
Fluourouracil (FU) is a mainstay of chemotherapy, although toxicities are common. Genetic
biomarkers have been used to predict these adverse events, but their utility is uncertain.
Patients and Methods
We tested candidate polymorphisms identified from a systematic literature search for associations
with capecitabine toxicity in 927 patients with colorectal cancer in the Quick and Simple and
Reliable trial (QUASAR2). We then performed meta-analysis of QUASAR2 and 16 published
studies (n  4,855 patients) to examine the polymorphisms in various FU monotherapy and
combination therapy regimens.
Results
Global capecitabine toxicity (grades 0/1/2 v grades 3/4/5) was associated with the rare, functional
DPYD alleles 2846TA and *2A (combined odds ratio, 5.51; P  .0013) and with the common
TYMS polymorphisms 5VNTR2R/3R and 3UTR 6bp ins-del (combined odds ratio, 1.31; P  9.4 
106). There was weaker evidence that these polymorphisms predict toxicity from bolus and
infusional FU monotherapy. No good evidence of association with toxicity was found for the
remaining polymorphisms, including several currently included in predictive kits. No polymor-
phisms were associated with toxicity in combination regimens.
Conclusion
A panel of genetic biomarkers for capecitabine monotherapy toxicity would currently comprise
only the four DPYD and TYMS variants above. We estimate this test could provide 26% sensitivity,
86% specificity, and 49% positive predictive value—better than most available commercial kits,
but suboptimal for clinical use. The test panel might be extended to include additional, rare DPYD
variants functionally equivalent to *2A and 2846A, though insufficient evidence supports its use in
bolus, infusional, or combination FU. There remains a need to identify further markers of FU
toxicity for all regimens.
J Clin Oncol 32:1031-1039. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Fluorouracil (FU) is the backbone of chemotherapy
for colorectal cancer and many other solid tumors.
Three methods are used to deliver FU: bolus
infusional intravenous administration, and oral
capecitabine, a prodrug that undergoes preferential
conversion to FU in malignant tissue. Oxaliplatin or
irinotecan can be added to FU in combination regi-
mens that include infusional fluorouracil, leuco-
vorin, and oxaliplatin (FOLFOX)1; capecitabine
plus oxaliplatin (XELOX)2; and fluorouracil, leuco-
vorin, and irinotecan (FOLFIRI).3 Depending on
the regimen used, 10% to 30% of patients suffer
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substantial FU toxicities (grade  3), typically diarrhea, nausea and
vomiting, mucositis/stomatitis, myelosuppression, and hand-foot
syndrome (HFS). Overall, FU causes 0.5% to 1.0% mortality (grade
5).4,5 Consequently, attention has focused on the identification of
biomarkers or assays predictive of FU toxicity.6,7
FU metabolism involves many enzyme reactions and interme-
diates (Data Supplement [online only]). Although measurement of
enzyme activities could be used for toxicity prediction, these assays
may be too cumbersome and expensive for routine, large-scale use.
After initial reports linking severe dihydropyrimidine dehydroge-
nase (DPYD) deficiency with lethal FU use,8 many genetic poly-
morphisms and rare variants in FU metabolism genes have been
reported to influence the risk of adverse events.9-11 In theory, by
testing a panel of polymorphisms, FU toxicities can be predicted
and dose modifications considered. However, the existing pub-
lished data are limited by inconsistency in reporting and testing
toxicities, pooling of patients on different FU schedules, and com-
bined analysis of functionally distinct polymorphisms within the
same gene. Several polymorphisms lacking validation may have
been included in commercial FU toxicity kits.
Given the uncertainty regarding which genetic variants are truly
predictive of adverse events from FU, we have examined associations
between candidate polymorphisms and capecitabine toxicity in pa-
tients from the Quick and Simple and Reliable trial (QUASAR2). We
have then performed a meta-analysis combining these data with those
from previously published studies, both of capecitabine and other
FU schedules.
PATIENTS AND METHODS
A synopsis of the methods used is presented here. Full details are provided in
the Data Supplement.
The QUASAR2 study was the basis of our analysis of genetic markers of
capecitabine toxicity. QUASAR2 is a phase III randomized trial of adjuvant
capecitabine  bevacizumab after resection of stage II/III colorectal cancer.
We obtained data from 927 patients from the QUASAR2 trial for common
FU-related toxicities—diarrhea, nausea and vomiting, mucositis/stomatitis,
neutropenia, thrombocytopenia, and HFS. Adverse toxicity events were cate-
gorized as high (Common Terminology Criteria for Adverse Events grades 3,
4, or 5 during any treatment cycle) or low (grades 0, 1, or 2). A global toxicity
measure was derived based on the presence of any grade 3/4/5 event (high) or
absence of any such event (low).
From a systematic literature review (Data Supplement), we identified 36
FU-pathway polymorphisms potentially suitable for analysis (Table 1; Data
Supplement). QUASAR2 genotypes were derived from Illumina (San Diego,
CA) SNP arrays, individual polymorphism typing assays, or genetic imputa-
tion as long as high-quality results were obtained (Data Supplement). Twenty-
one polymorphisms were included in the final analysis, after quality control
and the exclusion of variants in strong pairwise linkage disequilibrium. They
were CES2823CG, CES2rs11568314, CES2rs11568311, CES2rs2241409,
CDA451CT, CDA*2, UMPS638GC, TYMPrs470119, TYMPS471L,
TYMS5VNTR2R/3R, TYMS3UTR 6bp ins-del, MTHFR677CT,
MTHFR1298AC, DPYD85TC, DPYD496AG, DPYD1236GA,
DPYD1601GA, DPYD1627AG, DPYD*2A, DPYD2194GA,
and DPYD2846TA.
For meta-analysis of genetic predictors of FU toxicity, studies were
identified by systematic review.6,9-35 Sixteen studies fulfilled our inclusion
criteria.9-11,13,18,19,21,23,24,26,28-31,33,35 We did not perform formal, com-
bined analyses across regimens (Data Supplement). For every polymor-
phism in the meta-analysis (those analyzed for QUASAR2 plus
CES26046GA, CES26320GA, CDA205CG, CDArs602950,
CDA943insC, CDA575CT, CDA794GA, CDA771 CG,
UMPS1336AG, TYMPA324A, TYMS5VNTR3RGC, DPYD623GA,
DPYD1109delTA, DPYD1679TG, and DPYD2858GC), we performed
an allelic test of association with global toxicity (grades 0/1/2 v 3/4/5) in
each set of patients who had received the same regimen. For each FU
regimen, meta-analyses assessing the relationship between toxicity (global
and individual) and each individual polymorphism were performed using
the metan command in STATA (STATA, College Station, TX). SEs and
log(risk ratio) from each study were combined using the Mantel-Haen-
szel method.
For certain variants in TYMS and DPYD, we performed haplotype
and/or set-based tests. The TYMS5VNTR repeat haplotype with the
GCSNP in the second repeat was analyzed by a binary model based on
the total number of USF1/USF2 binding sites across both alleles (0 to 2 v 3
to 4).36 The TYMS5VNTR (2R v 3R) and 3UTR polymorphisms, which
are in moderate linkage disequilibrium, were analyzed in combination by
logistic regression conditioned on study, formal haplotype analysis, and a
score test in which toxicity was regressed on the number of TYMS toxicity
risk alleles (0 to 4) summed from the 3UTR and 5VNTR polymorphisms.
For DPYD, we grouped rare variants with effects on enzyme function
(DPYD*2A and 2846TA) for analysis.
For our primary investigation of global toxicity, we used a false discovery
rate of q  0.05,37 corresponding to P  .0065 for the QUASAR2 analysis,
P  .0033 for the capecitabine meta-analyses, and P  .0048 for the noncape-
citabine meta-analyses. We refer to associations that achieve q  0.05 as
formally significant and those that achieve P .05 as nominally significant. We
also applied these thresholds to assessment of individual toxicities, because
these are not independent of global toxicity.
RESULTS
Testing Candidate FU-Toxicity Variants in QUASAR2
Of 927 patients on the QUASAR2 study, 301developed grade  3
global toxicity. The most frequent specific grade  3 toxicity was HFS
(n  206), followed by diarrhea (n  97), and neutropenia (n  19).
Two patients died as a result of capecitabine-related toxicity; one as a
result of respiratory failure second to neutropenia and the other as a
result of neutropenic colitis and left ventricular hypertrophy. Three of
the 21 polymorphisms were significantly associated with global G3	
toxicity at q  0.05: TYMS5VNTR2R (odds ratio [OR], 1.49; P 
7.2  105), TYMS3UTR6bp ins (OR, 1.36; P  .0051), and
DPYD2846A (OR, 9.35; P  .0043; Table 2). We found no formally
significant effect of the other 18 previously reported FU variants on
global or specific toxicities (Data Supplement).
The 5VNTR and 3UTRTYMS polymorphisms are in moderate
linkage disequilibrium (r2  0.17; D  0.64). In logistic regression
analysis incorporating both variants, only the 5VNTR polymorphism
remained significantly associated with toxicity (Table 2). However,
there was modest evidence from the logistic regression analysis that
the 3UTR genotype might have some independent association with
toxicity (OR, 1.22; P  .10; Table 2), and a regression model with both
5VNTR and 3UTR had a slightly better fit to the data than a model
with 5VNTR alone (Aikake information criterion, 1,142 v 1,143). To
capture the combined signal from the 5VNTR and 3UTR polymor-
phisms, we also tested a quantitative TYMS risk score (count, 0 to 4;
according to the number of high-risk alleles per patient). The risk
score was approximately normally distributed (P  .76, Shapiro-Wilk
test) and strongly predicted global FU toxicity (ORper count, 1.33; P 
1.7105; Table 2; ORscore 3 or 4 v score 0, 2.91; 95% CI, 1.43 to 5.94; P
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.0032), providing a slightly improved fit (Aikake information crite-
rion, 1,140) to the data.
We then analyzed the individual toxicities underlying the
significant associations with global toxicity. The TYMS polymor-
phisms (score test) seemed to have similar effects on HFS (OR,
1.30; P  .00052) and diarrhea (OR, 1.24; P  .038), but the former
toxicity was more common and hence contributed more to the
global measure (Table 2). In contrast, the effects of DPYD2846A
seemed more marked for diarrhea (OR, 3.14; P  .093) than for
HFS (OR, 1.31; P  .69; Table 2).
Meta-Analysis of FU-Toxicity Variants
Effect of variants on toxicity from capecitabine monotherapy.
Fifteen variants were analyzed for associations with global capecit-
abine toxicity (Data Supplement). The four studies additional to
QUASAR2 comprised up to 382 patients. For TYMS and DPYD2A,
the conclusions from the QUASAR2 analysis were maintained in
the meta-analysis (Table 2; Fig 1). We found no good evidence of
an association between any other polymorphism and G3	 toxicity
(Data Supplement).
Effect of variants on toxicity from infusional FU monotherapy.
Fifteen variants were analyzed (Data Supplement), of which seven
were present in single studies only. Only TYMS 5VNTR2R met the
formal significance threshold for association with global G3	 tox-
icity in the meta-analysis (OR, 1.45; 95% CI, 1.13 to 1.85; P 
.0035; Data Supplement). In an analysis adjusted for the 3UTR6bp
ins-del variant (Data Supplement), the 5VNTR polymorphism
remained associated with toxicity (OR, 1.53; 95% CI, 1.14 to 2.04;
P  .0040). The TYMS risk score was only nominally associated
with toxicity (ORper count, 1.22; 95% CI, 1.02 to 1.45; P  .031).








Coordinate MAF (%) Past Kit Studies
Pro-drug activation CES2 First of three
steps in converting
capecitabine to FU
823 (830) C/G 5’UTR rs11075646 8 Y 2
Intronic SNP rs11568314 6 1
Intronic SNP rs11568311 7 1
6046GA; R270H rs8192924 1 1
6320 G/A chr16:65532174 0.8 1
Intronic SNP rs2241409 16 1
CDA (CDD) Second of three steps
in converting
capecitabine to FU
-451CT rs532545 34 Y 1
-205CG rs603412 50 1
5’UTR SNP rs602950 rs602950 35 1
943insC rs3215400 42 Y 2
CDA2; 79AC; K27Q rs2072671 34 2
575 C/T chr1:20817782 40 1
794 G/A chr1:20817822 6 1
771 C/G chr1:20817978 46 1
UMPS (OPRT) Conversion of FU to FUMP 638GC (Gly213Ala) rs1801019 20 1
1336AG (Ile446Val) rs3772809 0.6 1
TYMP (TP) Conversion of FU to FUDR Intronic SNP rs470119 rs470119 39 1
A324A rs131804 40 1
S471L rs11479 14 1
5-FU target TYMS (TS) Necessary for DNA synthesis;
target of FU
5’VNTR 3R G/C SNP rs2853542 50 Y 10
5’VNTR 2R/3R rs45445694 47 Y Y 18
3’UTR 1494indel6b rs16430 31 Y Y 18
MTHFR Lowers levels of
folate-derived TYMS cofactor
677CT; A222V rs1801133 32 Y Y 18
1298AC; E429A rs1801131 33 Y Y 14
Catabolism DPYD (DPD) First catabolic step
of activated drug (up to 80%,
mostly in liver)
9A; 85TC; C29R rs1801265 23 Y Y 6
496AG; M166V rs2297595 9 Y 4
623GA; R208Q chr1:97937552 ND 1
1109delTA chr1:97831380 ND 1
1236GA; E412E rs56038477 2 3
4A; 1601GA; S534N rs1801158 2 Y 3
5; 1627AG; I543V rs1801159 20 4
13; 1679TG; I560S rs55886062 0.1 Y 1
2A; IVS14	1GA rs3918290 0.4 Y Y 9
6; 2194GA; V732I rs1801160 3 3
2846TA; D949V rs67376798 0.6 Y Y 6
2858GC; C953S chr1:97320523 ND 1
NOTE. Polymorphisms have been described in various ways and these names are all shown, together with their dbSNP ID (rs number) or, where absent from
dbSNP, by chromosomal location in genome build hg18. Past refers to previously published associations at P  .1 for increased FU toxicity. Kit refers to inclusion
in a commercially available kit for predicting FU toxicity. Studies refer to the number of eligible, published studies that have analyzed this polymorphism for an
association with FU toxicity (excluding QUASAR2).
Abbreviations: dbSNP ID, database of SNPs identifier; DPYD, dihydropyrimidine dehydrogenase; FU, fluourouracil; MAF, minor allele frequency; ND, not
determined; QUASAR2, Quick and Simple and Reliable 2 trial; Y, yes.
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Analysis of individual adverse events suggested that the increased
toxicity with the TYMS5VNTR2R allele was primarily owing to
diarrhea (OR, 1.45; 95% CI, 1.01 to 2.08; P  .042).
Although it did not reach the formal significance level for associ-
ation, a substantial increased risk of global G3	 toxicity was suggested
for the DPYD*2A polymorphism (OR, 6.71; 95% CI, 1.66 to 27.1; P 
.0075), mainly because of diarrhea (OR, 7.71; 95% CI, 1.61 to 36.9;
P  .011). In a single-study analysis, the DPYD2846A allele showed a
trend to greater G3	 toxicity, though this did not reach significance
(OR, 3.09; 95% CI, 0.28 to 34.4; P  .36). None of the other FU-
toxicity variants analyzed showed significant associations with infu-
sional FU toxicity.
Effect of variants on toxicity from bolus FU monotherapy. The only
polymorphism significantly associated with global G3	 toxicity as a
result of bolus FU was the TYMS3UTR6bp ins allele (OR, 1.98; 95%
CI, 1.15 to 3.40; P  .00038), principally because of mucositis (OR,
2.03; 95% CI, 1.34 to 3.08; P  .00086; Data Supplement). However,
this association was not significant after adjusting for 5VNTR alleles
(Data Supplement). The TYMS risk score was a weaker predictor (OR,
1.35; 95% CI, 1.06 to 1.71; P  .014).
Although the DPYD*2A variant did not meet the formal level
of significance for association with global G3	 toxicity (OR, 3.84;
95% CI, 0.95 to 15.6; P  .059), a substantial and significant
increase in G3	 neutropenia was evident in patients who carried
A
B
ytienegoreteH      
 Patient Set OR 95% CI n P P
TYMS 5'VNTR
2–repeat allele
  Caronia 1.42 0.86 to 2.33 128
 Largillier 0.88 0.44 to 1.75 79
 QUASAR2 1.49 1.22 to 1.81 921
  Ribelles 1.13 0.67 to 1.90 123
 Sharma 0.37 0.10 to 1.43 52
 Overall 1.36 1.15 to 1.60  < .001 .17
TYMS 3'UTR
6bp–ins allele
 Caronia 1.28 0.76 to 2.13 130
 Largillier 0.52 0.26 to 1.04 80
 QUASAR2 1.36 1.10 to 1.69 923
 Sharma 1.02 0.34 to 3.03 54
 Overall 1.25 1.04 to 1.51  .02 .076
TYMS Score Test
n toxicity alleles
 Caronia 1.21 0.89 to 1.63 128
 QUASAR2 1.33 1.17 to 1.52 917
 Overall 1.31 1.16 to 1.48  < .001 .56
ytienegoreteH      
 Patient Set OR 95% CI n P P
DPYD*2A
A–allele Caronia 4.12 0.17 to 102.2 130
 QUASAR2 2.78 0.62 to 12.48 905
 Overall 3.02 0.78 to 11.70  .11 .83
Favors more toxicityFavors less toxicity
1.00.3 3.0
Favors more toxicityFavors less toxicity
1.00.1 15.0
Fig 1. Forest plots of meta-analyses of selected (A) TYMS and (B) DPYD polymorphisms associated with global capecitabine toxicity. The analyses shown are for global
grade  3 v grade 0 to 2 toxicities under a fixed-effects model. DPYD2846 is not shown because data were only available for the Quick and Simple and Reliable
(QUASAR2) study. Horizontal lines show the 95% CIs. The size of the square is directly proportional to the amount of information contributed by the trial. The diamonds
represent overall odds ratio (OR) for the included studies, with the center denoting the OR and the extremities the 95% CI.
FU Toxicity Genetics Meta-Analysis
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this variant (OR, 12.9; 95% CI, 3.13 to 53.3; P  .0004). As for
infusional FU, patients who carried the DPYD2846A allele had
trends to all types of toxicity. No other variant was significantly
associated with bolus FU toxicity.
Combined Analysis of Rare DPYD Alleles With
Evidence of Effects on Enzyme Function
For alleles within a single gene that have equivalent functional
effects causally related to toxicity, it is justifiable to combine these into
one functional class for predictive testing. For DPYD, some rare vari-
ants have been proposed to cause DPYD deficiency syndrome (Online
Mendelian Inheritance in Man No. 274270).38,39 Of these, a few have
been shown to reduce DPYD activity in vitro,40 whereas others have
lesser functional evidence from in vivo reports.41,42 Among variants
found in our patient sets, we found good published evidence of func-
tionality for DPYD2846A and *2A,38,39 but not for *9A (85TC) or
Ile370Val (1108AG), despite these having previously been reported
as causing DPYD deficiency (Data Supplement). We therefore per-
formed an analysis of DPYD2846TA and *2A rare alleles as a group
(presence of either variant v no either variant). We found a formally
significant association with global toxicity for capecitabine (OR, 5.51;
95% CI, 1.95 to 15.51; P  .0013; data from QUASAR2 alone; Table 2)
and nominally significant associations in the analyses for infusional
(P  .042) and bolus (P  .0068) monotherapies (Data Supplement).
All of these associations were stronger than when either of the variants
was considered alone. We noted that of the two patients who died
from capecitabine-related toxicity in QUASAR2, one carried
DPYD2846A and the other, *2A.
Prediction of Toxicity in FU Combination
Therapy Regimens
None of the polymorphisms analyzed was associated with
global or any specific toxicity in the combination therapy regimens
(FOLFOX; CAPOX [capecitabine and oxaliplatin]; FOLFIRI; irinote-
can, leucovorin, and fluorouracil [IFL or FLIRI]; Data Supplement).
We note that DPYD*2A was invariant and DPYD2846TA was not
analyzed in the available datasets. Figure 2 shows the results from
meta-analysis of the two main TYMS polymorphisms in studies using
FOLFOX, the largest combination therapy data set.
Performance of Panels of Polymorphisms for
Predicting FU Toxicity
There are currently three commercially available kits for predict-
ing FU toxicity (Data Supplement). These kits contain a total of 17
polymorphisms that fall into three categories: evidence of toxicity
prediction in our analysis (n  4), present in our analysis but without
good evidence of predictive ability (n  5), or absent from our analysis
(n  8). Of the variants that are absent from our analysis, five are rare
DPYD variants with evidence of harmful effects on enzyme function
[1679(*13), 1897(*3), 295-298del(*7), 703(*8), and 2983(*10);
Data Supplement].38,39
In QUASAR2, we assessed the prediction of global toxicity by
each kit, following the instructions as closely as possible, and using a
binary classification of risk (no/low v moderate/intermediate/high).
Owing to the inclusion of some common polymorphisms, two kits
classified almost all patients as at-raised-risk of toxicity. One kit,
however, provided better discrimination, with an area under the
      Heterogeneity
 Patient Set OR 95% CI n P P
TYMS 5'VNTR
2–repeat allele
  Boige 0.99 0.59 to 1.67 169
 Braun 0.56 0.32 to 0.95 163
 Etienne-Grimaldi 0.99 0.51 to 1.90 103
 Martinez-alibrea 1.29 0.56 to 2.98 48
 McLeod 0.91 0.61 to 1.36 243
 Overall 0.87 0.68 to 1.11  .26 .42
TYMS 3'UTR
6bp–ins allele
 Boige 0.93 0.55 to 1.56 173
 Braun 0.80 0.47 to 1.39 157
 Etienne-Grimaldi 1.09 0.54 to 2.22 108
 McLeod 1.27 0.83 to 1.92 248
 Overall 1.03 0.79 to 1.34  .80 .60
Favors more toxicityFavors less toxicity
1.00.3 3.0
Fig 2. Forest plot of TYMS polymorphisms meta-analyzed in infusional fluorouracil, leucovorin, and oxaliplatin patients. Horizontal lines show the 95% CIs. The size
of the square is directly proportional to the amount of information contributed by the trial. The diamonds represent overall odds ratios (OR) for the included studies,
with the center denoting the OR and the extremities the 95% CI.
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concentration-time curve of 0.56, 31% sensitivity, 82% specificity,
46% positive predictive value, and 70% negative predictive value
(Data Supplement).
We then assessed whether we could improve on the performance
of the kits using our DPYD combined rare functional alleles test and
the TYMS score test (Fig 3; Data Supplement). Although no fully
independent data set was available for cross-validation, we minimized
bias by applying effect size estimates from Caronia et al33 to QUASAR2
in a logistic regression model. Area under the concentration-time
curve was 0.61. At our preferred ln(OR) cutoff of 0.762, sensitivity was
26%, specificity was 86%, positive predictive value was 49%, and
negative predictive value was 70%.
DISCUSSION
We have provided the most comprehensive analysis to date of FU
toxicity pharmacogenetics. We found that few genetic variants had
convincing evidence of an association with toxicity. Of 36 previ-
ously assessed polymorphisms, only four—TYMS 5VNTR 2R/3R,
TYMS 3UTR 6bpins-del, DPYD 2846TA, and DPYD *2A—were
formally associated with global G3	 toxicity in our analysis. Even so,
associations were only present in FU monotherapy regimens. The best
evidence came from capecitabine monotherapy in the adjuvant setting
although, even here, TYMS3UTR6bp ins-del showed evidence of
interstudy heterogeneity and we therefore relied on the larger capecit-
abine studies for our conclusions regarding this polymorphism. Stud-
ies of bolus and infusional FU generally supported the TYMS and
DPYD data, although formally significant associations were less com-
mon. We found that formal cross-regimen analysis was not justifiable.
The TYMS risk alleles are common in the northern European
population. We found the two TYMS polymorphisms to be partially
independent toxicity predictors and both seem to provide useful in-
formation. Despite some inconsistent evidence that the TYMS alleles
affect mRNA expression levels,36,43 they have not been shown to cause
clinically significant differences in TYMS activity or thymidine incor-
poration into nucleic acids. Because the identity of the functional
TYMS variation that causes toxicity is unknown, we have proposed the
use of an ad hoc test in which each individual has a score of 0 to 4
according to the number of high-risk alleles they carry at the 5VNTR
and 3UTR polymorphisms. The score test was a good predictor of
global toxicity for capecitabine (OR, 1.33 per allele), with weaker
evidence for infusional and bolus FU monotherapy.
For DPYD, the two variants associated with toxicity are rare, but
for patients with *2A or 2846A, the risk is relatively high (OR, 5.51).
We have proposed a group test in which, on the basis of enzyme
function, patients carrying either DPYD2846A or DPYD*2A are
classed as being variant or wildtype. It is likely that other rare DPYD
variants with functional effects equivalent to 2846A or *2A could be
included in this test (Data Supplement).
Evidence of an association with toxicity was weak for the remain-
ing polymorphisms. Some of these (DPYD1627AG, DPYD85T
C, DPYD496AG, TYMS5VNTRGC, MTHFR677CT,
MTHFR1298AC, CDA451CT, CES2823CG, and the TYMP
polymorphisms) have common alleles (MAF  8%). Power to detect an
association for these SNPs was approximately 75% to 100%, assuming an
odds ratio of 1.5 per allele, and all but modest effects could therefore be
excluded where sample sizes were relatively large. For other polymor-
phisms (eg, DPYD1601GA, DPYD1236GA, DPYD2194GA,
CDA943insC, and most CES2 polymorphisms), minor allele frequencies
were low or sample sizes small, leading to suboptimal power (approxi-
mately20%to40%)todetectanassociation.Thecasefortheseasmarkers
of toxicity remains unproven.
Several factors limited our ability to identify polymorphisms
associated with FU toxicity. First, the different incidences of individual
toxicity phenotypes among FU-based regimens required that we strat-
ify the meta-analyses by FU regimen. This conservative approach
decreased power, but prevented us from falsely combining data for
toxicity events resulting from different sources. This method also
required a larger number of tests, though most were not independent
and we corrected for false discovery. Second, in the meta-analysis,
there was a little evidence of publication bias; eight of 28 studies failed
to provide ORs, and the absence of individual patient data meant that
covariate-adjusted analyses were not generally possible. Third, there
was no large capecitabine study to validate QUASAR2. Fourth, studies
used different genotyping methods, although there was only good
evidence of deviation from Hardy-Weinberg equilibrium in two
TYMS 3UTR data sets, which were subsequently excluded.
In conclusion, we have found that four specific germline TYMS
and DPYD variants predict capecitabine toxicity. Although our anal-
ysis suggests that the polymorphisms may be predictive of toxicity in
other FU monotherapy regimens, the data are currently less clear and
these regimens are used uncommonly. We found no good evidence of
polymorphisms that predict toxicity in patients on FU combination
therapies, although no data were available for rare DPYD variants in
this context. The lack of an association between either of the TYMS
polymorphisms and toxicity in combination regimens is interesting
and might reflect reduced FU dosage in these regimens, overlapping
toxicities between drugs, confounding of FU toxicity by other more
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Fig 3. Receiver operating characteristic (ROC) analysis of the TYMS score
test and DPYD group test for predicting global capecitabine toxicity in the
Quick and Simple and Reliable (QUASAR2) trial capecitabine patients. Two
sensitivity/specificity cut points are marked. Cut points at the bottom-left of
the plot corresponds to the maximum proportion of patients correctly
classified, with a sensitivity of 4.4%, specificity of 99%, positive predictive
value of 73% (PPV; 95% CI, 45% to 91%), and negative predictive value of
68% (NPV; 95% CI, 64% to 71%), largely owing to rare DPYD variants. The
other cut point (64% correctly classified) affects more patients as a result of
utilizing TYMS genotypes and corresponds to a sensitivity of 26%, specificity
of 86%, PPV of 49% (95% CI, 40% to 58%), and NPV of 70% (95% CI, 66%
to 74%).
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Our findings strongly suggest the exclusion of several unwarranted
polymorphisms from the currently available FU toxicity tests, leading
to better performance at lower cost. Even then, a genetic test compris-
ing the validated polymorphisms—two TYMS variants and functional
DPYD variants—provides only modest predictive power. For genetic
tests to be used in clinical practice, there is a need to identify and
characterize additional FU toxicity variants. If such variants were
added to the panel of polymorphisms identified in our study, a genetic
test might well provide the ability to closely monitor patients who are
at increased risk of toxicity or to increase FU dosage in those who are at
low risk of toxicity.
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